Some studies suggest that adipsin/C3a could become a therapeutic target (lampalizumab-monoclonal antibody against adipsin), considering that adipsin is a mediator of the adipose–epithelial breast cell interaction that enhances proliferation and cancer stem cell properties of breast cancer cells [32] (p. 13). Here, CFD is linked to breast carcinoma.